Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EXSEL vs LOTRIMIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Exsel (selenium sulfide) is an antifungal agent that reduces the production of cutaneous oils and exerts cytostatic effects on epidermal cells. It inhibits the growth of Pityrosporum ovale and other fungi by interfering with oxidative enzyme systems, leading to decreased sebum production and normalization of epidermal turnover.
Clotrimazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Treatment of tinea versicolor (pityriasis versicolor),Management of dandruff and seborrheic dermatitis of the scalp
Topical treatment of tinea pedis, tinea cruris, tinea corporis, tinea versicolor, and cutaneous candidiasis,Vaginal treatment of vulvovaginal candidiasis
1-2 mg orally once daily; maximum dose 2 mg/day.
Clotrimazole 1% cream or solution applied topically to affected area twice daily for 2-4 weeks. For vaginal tablets: 100 mg intravaginally once daily for 7 days or 500 mg single dose. For troches: 10 mg troche dissolved slowly in mouth five times daily for 14 days.
Terminal half-life: 12-18 hours (mean 15 h); requires dose adjustment in renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life is approximately 20-50 hours. Dose adjustments not required in renal impairment, but caution in hepatic impairment.
Minimal systemic absorption after topical application; any absorbed selenium is primarily excreted in urine, with minor metabolism via reduction to selenides and methylation to dimethylselenide.
Hepatic metabolism via CYP3A4 and CYP2C9; excreted in feces and urine as metabolites.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
Approximately 70% of absorbed dose is excreted in feces as unchanged drug and metabolites; about 20% is excreted renally as metabolites with less than 1% unchanged. Biliary excretion is a minor route.
95% bound to albumin and alpha-1-acid glycoprotein.
Approximately 98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
0.8-1.2 L/kg; indicates extensive extravascular distribution.
Volume of distribution is approximately 2.5-4.0 L/kg, indicating extensive tissue distribution.
Oral: 60-80%; first-pass metabolism reduces bioavailability by 20-40%.
Topical: minimal systemic absorption (<0.5%). Oral: not available; vaginal: approximately 3-10% systemic absorption.
No adjustment required for mild to moderate impairment. Severe impairment (GFR <30 m L/min): contraindicated.
No dose adjustment required for topical or vaginal use. For troches, no data available; however, systemic absorption is minimal.
Child-Pugh A: no adjustment. Child-Pugh B or C: contraindicated.
No dose adjustment required for topical or vaginal use. For troches, use with caution in severe hepatic impairment due to limited data.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Topical: Apply to affected area twice daily for 2-4 weeks (safe for all ages). Vaginal: Not recommended in prepubertal children. Troches: Not recommended for children under 5 years due to risk of choking; for children ≥5 years, same dose as adults (10 mg troche five times daily).
Start at 1 mg orally once daily; titrate cautiously due to increased risk of falls and hypotension.
No specific dose adjustment required. Use same dosing as adults. Consider skin fragility with topical application.
None.
None
Avoid contact with eyes, eyelids, and mucous membranes. If contact occurs, rinse thoroughly with water. Discontinue if local irritation or sensitization develops. Use with caution in patients with inflamed or broken skin due to increased absorption risk. Not for use on large areas of the body for prolonged periods.
For external use only; avoid contact with eyes; discontinue if hypersensitivity occurs; not for ophthalmic or oral use; use in pregnancy only if clearly needed (Category B).
Hypersensitivity to selenium sulfide or any component of the formulation. Do not use on broken or inflamed skin.
Hypersensitivity to clotrimazole or any component of the formulation
No known food interactions.
No known significant food interactions.
Pregnancy Category D. First trimester: Associated with Ebstein's anomaly and other congenital heart defects; avoid if possible. Second and third trimesters: Risk of fetal hyperthyroidism or hypothyroidism, cranial synostosis, intellectual disability, and neonatal goiter if maternal hyperthyroidism is treated with this drug. Use only if clearly needed and maternal benefit outweighs fetal risk.
Clotrimazole (LOTRIMIN) topical use is not associated with increased risk of major congenital malformations. Systemic absorption is minimal (<0.5% after vaginal or topical application). First trimester vaginal use has insufficient data, but no clear teratogenic signal. Second and third trimester vaginal use is considered safe. Overall, risk is low due to negligible systemic exposure.
Excreted in human milk. M/P ratio not available. Potential for serious adverse reactions in nursing infants, including thyroid dysfunction and arrhythmias. Decision to discontinue nursing or drug based on importance of drug to mother.
Minimal systemic absorption after topical or vaginal use leads to negligible excretion into breast milk. M/P ratio is not applicable due to undetectable levels. Suitable for use during breastfeeding. No adverse effects reported in nursing infants.
Pregnancy may increase clearance of this drug; dose adjustments often not required, but individualize based on maternal thyroid function and clinical response. Lower doses may be needed to avoid fetal hypothyroidism.
No dose adjustment required during pregnancy. Pharmacokinetics of topical/vaginal clotrimazole are unchanged due to minimal systemic absorption. Standard dosing (e.g., 100 mg vaginal tablet for 7 days or 500 mg single dose) is appropriate.
EXSEL (selenium disulfide) 2.5% shampoo: Use twice weekly for 2 weeks, then once weekly for maintenance. Limit application to 5-10 minutes before rinsing. Avoid contact with eyes or broken skin. Can cause temporary hair discoloration (especially on bleached or permed hair). May stain jewelry and clothing. For dandruff and seborrheic dermatitis of the scalp.
Clotrimazole is a broad-spectrum antifungal agent; Topical formulations (cream, solution, lotion) are preferred for dermatophytosis; Vaginal tablets must be inserted high into the vagina; Avoid use on broken or inflamed skin; Monitor for local irritation.
Shake bottle well before use.,Wet hair thoroughly before applying shampoo.,Apply enough shampoo to lather and massage into scalp for 2-3 minutes.,Leave on scalp for 5 minutes (up to 10 minutes) before rinsing thoroughly.,Rinse hair and scalp completely to avoid residue.,Use twice weekly for first 2 weeks, then once weekly as directed.,Avoid contact with eyes; if contact occurs, rinse thoroughly with water.,Do not use on broken or irritated skin.,Discontinue use and consult doctor if rash or irritation develops.,May stain clothing and jewelry; rinse thoroughly after use.
Apply the medication to the affected area as directed, usually twice daily.,Wash hands before and after application unless treating hands.,For vaginal tablets, insert one tablet deep into the vagina at bedtime for 3 or 7 days.,Complete the full course even if symptoms improve.,Avoid tight-fitting clothing and synthetic fabrics; keep area clean and dry.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EXSEL vs LOTRIMIN, answered by our medical review team.
EXSEL is a Topical Antifungal that works by Exsel (selenium sulfide) is an antifungal agent that reduces the production of cutaneous oils and exerts cytostatic effects on epidermal cells. It inhibits the growth of Pityrosporum ovale and other fungi by interfering with oxidative enzyme systems, leading to decreased sebum production and normalization of epidermal turnover.. LOTRIMIN is a Topical Antifungal that works by Clotrimazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EXSEL and LOTRIMIN depend on the specific clinical indication. These are both Topical Antifungal agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EXSEL is: 1-2 mg orally once daily; maximum dose 2 mg/day.. The standard adult dose of LOTRIMIN is: Clotrimazole 1% cream or solution applied topically to affected area twice daily for 2-4 weeks. For vaginal tablets: 100 mg intravaginally once daily for 7 days or 500 mg single dose. For troches: 10 mg troche dissolved slowly in mouth five times daily for 14 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EXSEL and LOTRIMIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EXSEL is classified as Category C. Pregnancy Category D. First trimester: Associated with Ebstein's anomaly and other congenital heart defects; avoid if possible. Second and third trimesters: Risk of fetal hyperthyr. LOTRIMIN is classified as Category C. Clotrimazole (LOTRIMIN) topical use is not associated with increased risk of major congenital malformations. Systemic absorption is minimal (<0.5% after vaginal or topical applicat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.